HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US OTC Monograph Reform's Early Results Could Be Label Orders From FDA, Wait And See For Industry

Executive Summary

With much of FDA's work currently focused on the COVID-19 pandemic, the agency has limited resources available to implement monograph changes authorized by recent legislation. Drug firms awaited a monograph overhaul with expectations for success where they previously failed, but they need FDA's guidance to succeed.

You may also be interested in...



Regulation Of US Supplement Industry Needs ‘Really Hard Look’ – FDA's Woodcock

Acting commissioner's comment on supplement industry regulation was her most definitive statement about the agency’s work in consumer health sector at CHPA's regulatory conference. Pandemic, she says, heightened consumer interest in self-care along with demand for OTC drugs and supplements.

OMOR Or Not To OMOR: Proposals Will Push US OTC Monograph Fees Past Requested Level

Payments FDA receives could expand from facility fees between $13,548 and $20,322 collected from around 1,700 firms for the current fiscal year to include payments of $500,000 or $100,000 from firms for proposed monograph changes.

ACI’s Antiseptic Testing Continues Under Specter Of FDA Administrative Order

The American Cleaning Institute is preparing to submit a healthcare personnel hand wash study to the US FDA pending confidentiality discussions, along with results from a literature review on the topic of antimicrobial resistance. A progress report is due to the agency in October, which could stave off an administrative order under the reformed OTC drug review system.

Related Content

Topics

UsernamePublicRestriction

Register

RS149918

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel